Sale!

Comprehensive Tumor Panel 320 Genes

Original price was: $1,000.Current price is: $826.

-17%

The Comprehensive Tumor Panel 320 Genes is an advanced next-generation sequencing test that analyzes 320 cancer-related genes to identify genetic mutations driving tumor growth. This comprehensive molecular diagnostic test provides crucial information for personalized cancer treatment planning, helping oncologists select targeted therapies and immunotherapy options. The test detects single nucleotide variants, insertions, deletions, copy number variations, and gene fusions across key cancer pathways. Patients with various solid tumors can benefit from this detailed genetic profiling to guide treatment decisions and improve outcomes. Available for only $826 USD, this test offers significant cost savings from the regular $1000 price. Results are typically delivered within 21 working days from FFPE tissue block or fresh tissue samples.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Comprehensive Tumor Panel 320 Genes: Advanced Cancer Genetic Testing

Understanding Comprehensive Cancer Genetic Profiling

The Comprehensive Tumor Panel 320 Genes represents a cutting-edge molecular diagnostic approach that utilizes next-generation sequencing (NGS) technology to analyze 320 cancer-related genes simultaneously. This comprehensive genetic testing provides oncologists with detailed insights into the molecular drivers of cancer, enabling personalized treatment strategies based on the unique genetic profile of each patient’s tumor.

Cancer is fundamentally a genetic disease, and understanding the specific mutations present in tumor cells is crucial for effective treatment planning. Our 320-gene panel covers all major cancer pathways and therapeutic targets, offering a comprehensive view of the tumor’s genetic landscape that goes beyond traditional single-gene testing.

What This Advanced Test Detects

The Comprehensive Tumor Panel 320 Genes identifies multiple types of genetic alterations across a broad spectrum of cancer-related genes:

  • Single Nucleotide Variants (SNVs): Point mutations that can activate oncogenes or inactivate tumor suppressor genes
  • Insertions and Deletions (Indels): Small insertions or deletions that can disrupt gene function
  • Copy Number Variations (CNVs): Amplifications or deletions of gene regions that affect cancer development
  • Gene Fusions: Chromosomal rearrangements that create novel fusion genes with oncogenic potential

The panel covers genes involved in DNA repair pathways, cell cycle regulation, growth factor signaling, apoptosis, and immune checkpoint regulation, providing a comprehensive molecular portrait of the tumor.

Who Should Consider This Comprehensive Genetic Testing

This advanced tumor profiling test is particularly valuable for patients with:

  • Advanced or metastatic solid tumors where targeted therapy options are being considered
  • Cancers with unclear primary origin that require molecular characterization
  • Rare or uncommon tumor types where standard treatment guidelines are limited
  • Cancers that have progressed on standard therapies and require alternative treatment strategies
  • Patients seeking eligibility for clinical trials requiring specific genetic biomarkers
  • Individuals with family history of cancer who want comprehensive tumor profiling

Significant Benefits of Comprehensive Tumor Genetic Analysis

Choosing our 320-gene tumor panel offers multiple advantages for cancer patients and their healthcare providers:

  • Personalized Treatment Selection: Identify targeted therapies matched to specific genetic alterations
  • Immunotherapy Guidance: Assess biomarkers for immune checkpoint inhibitor response
  • Clinical Trial Matching: Discover eligibility for novel targeted therapy trials
  • Comprehensive Molecular Profile: Single test covering multiple therapeutic targets and pathways
  • Treatment Resistance Insights: Understand mechanisms of resistance to previous therapies
  • Prognostic Information: Gain insights into tumor behavior and potential progression

Understanding Your Comprehensive Test Results

Your test report will provide detailed information about detected genetic alterations, including:

  • Actionable Mutations: Genetic changes with approved targeted therapies
  • Investigational Targets: Alterations with therapies in clinical development
  • Resistance Markers: Mutations that may confer resistance to specific treatments
  • Clinical Trial Matches: Potential eligibility for ongoing clinical studies
  • Variant Interpretation Professional assessment of clinical significance for each finding

Our molecular pathologists and genetic counselors are available to help you and your physician understand the results and their implications for your treatment plan.

Test Pricing and Sample Requirements

Test Name Discount Price Regular Price Turnaround Time
Comprehensive Tumor Panel 320 Genes $826 USD $1000 USD 21 Working Days

Sample Types Accepted: FFPE Tissue Block, Fresh Tissue

Nationwide Availability and Easy Booking

We have diagnostic centers conveniently located across the United States, serving major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network ensures accessible cancer genetic testing for patients nationwide.

Take the next step in your cancer care journey with comprehensive genetic profiling. Our advanced 320-gene tumor panel provides the detailed molecular information needed to guide personalized treatment decisions and explore all available therapeutic options.

Ready to schedule your Comprehensive Tumor Panel 320 Genes test? Call our dedicated oncology testing specialists today at +1(267) 388-9828 or book your appointment online. Our team will guide you through the sample collection process and answer any questions about this advanced genetic testing option.